Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the ‘burden of therapy’ methodMichael Haas, Volker Heinemann, Dirk Waldschmidt et al.|European Journal of Cancer|2021Cited by 34
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)Frank Griesinger, Dimitri Flieger, Bastian Jaeschke et al.|JTO Clinical and Research Reports|2023Cited by 4